Last reviewed · How we verify
Dolutegravir/lamivudine/abacavir
Dolutegravir/lamivudine/abacavir is a Antiretroviral combination (INSTI + NRTI backbone) Small molecule drug developed by Azienda Ospedaliera Universitaria Senese. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (age-appropriate formulations). Also known as: Triumeq.
This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase and reverse transcriptase enzymes while providing nucleoside backbone coverage.
This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase and reverse transcriptase enzymes while providing nucleoside backbone coverage. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (age-appropriate formulations).
At a glance
| Generic name | Dolutegravir/lamivudine/abacavir |
|---|---|
| Also known as | Triumeq |
| Sponsor | Azienda Ospedaliera Universitaria Senese |
| Drug class | Antiretroviral combination (INSTI + NRTI backbone) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Lamivudine and abacavir are nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcriptase, preventing conversion of viral RNA to DNA. Together, they provide complementary mechanisms to suppress HIV replication at multiple steps.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (age-appropriate formulations)
Common side effects
- Diarrhea
- Nausea
- Headache
- Insomnia
- Hypersensitivity reaction (abacavir)
- Hepatotoxicity
- Lactic acidosis (rare)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study of GS-1219 in Participants With HIV-1 (PHASE1)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir/lamivudine/abacavir CI brief — competitive landscape report
- Dolutegravir/lamivudine/abacavir updates RSS · CI watch RSS
- Azienda Ospedaliera Universitaria Senese portfolio CI
Frequently asked questions about Dolutegravir/lamivudine/abacavir
What is Dolutegravir/lamivudine/abacavir?
How does Dolutegravir/lamivudine/abacavir work?
What is Dolutegravir/lamivudine/abacavir used for?
Who makes Dolutegravir/lamivudine/abacavir?
Is Dolutegravir/lamivudine/abacavir also known as anything else?
What drug class is Dolutegravir/lamivudine/abacavir in?
What development phase is Dolutegravir/lamivudine/abacavir in?
What are the side effects of Dolutegravir/lamivudine/abacavir?
What does Dolutegravir/lamivudine/abacavir target?
Related
- Drug class: All Antiretroviral combination (INSTI + NRTI backbone) drugs
- Target: All drugs targeting HIV integrase, HIV reverse transcriptase
- Manufacturer: Azienda Ospedaliera Universitaria Senese — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in adolescents and children (age-appropriate formulations)
- Also known as: Triumeq
- Compare: Dolutegravir/lamivudine/abacavir vs similar drugs
- Pricing: Dolutegravir/lamivudine/abacavir cost, discount & access